Behavioural Brain Research
December 28, 2020
Anna U. Odland, Jesper L. Kristensen, Jesper T. Andreasen
60 citations
Psychedelic drugs acting as 5-hydroxyptryptamine 2A receptor (5-HT2AR) agonists have shown promise as viable treatments of psychiatric disorders, including obsessive-compulsive disorder. The marble burying test is a test of compulsive-like behavior in mice, and psychedelics acting as 5-HT2AR agonists can reduce digging in this test. We assessed the 5-HT2R contribution to the mechanisms of two...
ACS Pharmacology & Translational Science
December 14, 2020
Adam K. Klein, Muhammad Chatha, Lauren J. Laskowski et al.
103 citations
The 5-HT2A receptor is thought to be the primary target for psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and other serotonergic hallucinogens (psychedelic drugs). Although a large amount of experimental work has been conducted to characterize the pharmacology of psilocybin and its dephosphorylated metabolite psilocin (4-hydroxy-N,N-dimethyltryptamine), there has been little systematic...
ACS Pharmacology & Translational Science
December 9, 2020
Christopher S. Stauffer, B. Anderson, Kile Ortigo et al.
65 citations
Attachment insecurity is determined early in life, is a risk factor for psychopathology, and can be measured on two separate continuous dimensions: attachment anxiety and attachment avoidance. Therapeutic changes toward more secure attachment correlate with reduction in psychiatric symptoms. Psilocybin-assisted psychotherapy has demonstrated promise in the treatment of psychopathology, such as...
European Neuropsychopharmacology
December 4, 2020
Lene Lundgaard Donovan, Jens Vilstrup Johansen, Nídia Fernandez Ros et al.
45 citations
Psilocybin has in some studies shown promise as treatment of major depressive disorder and psilocybin therapy was in 2019 twice designated as breakthrough therapy by the U.S. Food and Drug Administration (FDA). A very particular feature is that ingestion of just a single dose of psilocybin is associated with lasting changes in personality and mood. The underlying molecular mechanism behind its...
Frontiers in Pharmacology
December 3, 2020
Daniela Dudysová, Karolína Janků, Michal Šmotek et al.
37 citations
Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we...
Journal of Neuroscience
November 30, 2020
Danilo de Gregorio, Argel Aguilar-Valles, Katrin H. Preller et al.
258 citations
A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of...
Journal of Psychoactive Drugs
November 22, 2020
Agustín Lugo-Radillo, Jorge Luis Cortés-lópez
34 citations
Obsessive Compulsive Disorder (OCD) is a chronic neuropsychiatric condition, characterized by obsessions and compulsions, which is usually disabling for the suffering individual. The first-line treatment is not effective in all patients. There is evidence showing the effectiveness of psilocybin and psilocybin-containing mushrooms in the treatment of OCD symptoms. We present the case of a male...
L'Encephale
November 12, 2020
Hugo Bottemanne, Anne Claret, Philippe Fossati
10 citations
The hypothesis of monoaminergic deficiency has long dominated the conceptual framework for the development of new antidepressant strategies, but the limits of conventional antidepressant treatments targeting monoaminergic signaling have motivated the search for new antidepressant pathways. The success of ketamine in the management of depressive disorders has provoked a renewed interest in...
Journal watch
November 6, 2020
Exploratory studies have examined the usefulness of the hallucinogen psilocybin for depressed cancer patients and patients with treatment-resistant
Journal of Psychopharmacology
November 4, 2020
Oskar Hougaard Jefsen, Betina Elfving, Gregers Wegener et al.
123 citations
Background: Psilocybin is a serotonergic psychedelic found in “magic mushrooms” with a putative therapeutic potential for treatment-resistant depression, anxiety, obsessive-compulsive disorder, and addiction. In rodents, psilocybin acutely induces plasticity-related immediate early genes in cortical tissue; however, studies into the effects on subcortical regions, of different doses, and the...